Drug-resistance

GSK and Spero Therapeutics Announce Exclusive License Agreement

1 min read

Home
News

GSK and Spero Therapeutics Announce Exclusive License Agreement

GlaxoSmithKline (GSK) plc and Spero Therapeutics, Inc. announced entering into a license agreement for tebipenem pivoxil hydrobromide (tebipenem HBr), a...

GSK and Spero Therapeutics Announce Exclusive License Agreement

Disease Overview: Duchenne Muscular Dystrophy

Promising Therapeutic Approaches for Spinal Muscular Atrophy (SMA)

FDA Approves Bylvay (Odevixibat) as a Breakthrough Treatment for Cholestatic Pruritus in Alagille Syndrome Patients

Comparing Enzalutamide and Flutamide as First-Line Androgen Therapy for Japanese Men with Castration-Resistant Prostate Cancer: A Clinical Study

GSK and Spero Therapeutics Announce Exclusive License Agreement

You may have missed

Disease Overview: Duchenne Muscular Dystrophy

Promising Therapeutic Approaches for Spinal Muscular Atrophy (SMA)

FDA Approves Bylvay (Odevixibat) as a Breakthrough Treatment for Cholestatic Pruritus in Alagille Syndrome Patients

Comparing Enzalutamide and Flutamide as First-Line Androgen Therapy for Japanese Men with Castration-Resistant Prostate Cancer: A Clinical Study